Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE1921.5583.6 (+4.55 %)

PREV CLOSE ( ) 1837.95

OPEN PRICE ( ) 1835.05

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 17452

TODAY'S LOW / HIGH ( )1835.05 1941.00

52 WK LOW / HIGH ( )1370.05 2658

NSE1920.5081.9 (+4.45 %)

PREV CLOSE( ) 1838.60

OPEN PRICE ( ) 1851.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1920.50 (1733)

VOLUME 624337

TODAY'S LOW / HIGH( ) 1835.30 1942.90

52 WK LOW / HIGH ( )1345 2664

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984

Management Info

Sudhir Vaid - Chairman Sudhir Vaid - Managing Director

Registered Office

Address 1482-1486 ,Trasad Road,Dholka,
Ahmedabad Dist,
Gujarat-382225

Phone 02714-222604 / 398200

Email complianceofficer@concordbiotech.com

Website www.concordbiotech.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

08Jul Concord Biotech informs about certific
In compliance with Regulation 74(5) of SEBI (Depositories and Participan..

02Jul Concord Biotech makes equity investmen
Concord Biotech has made an equity investment of $1,500 in Stellon Biote..

24Jun Concord Biotech gets EIR from USFDA fo
Concord Biotech has received an establishment inspection report (EIR) fr..

09Apr Concord Biotech gets final approval fr
Concord Biotech has been granted final approval from the United States F..

09Apr Concord Biotech surges after getting f
Concord Biotech is currently trading at Rs 1619.15, up by 21.35 points o..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	1419.37	3729.65
Gross Profit	1850.94	4958.76
Operating Profit	1998.07	5507.79
Net Sales	4298.84	12000.87

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE) 9386.25 (2.44%)	M.Cap ( in Cr)23465.63
Neuland Laboratories (BSE) 14496.35 (0.67%)	M.Cap ( in Cr)18598.66
Hester Biosciences (BSE) 1946.45 (4.57%)	M.Cap ( in Cr)1655.82
Sanofi India (BSE) 5955.65 (1.12%)	M.Cap ( in Cr)13716.23
Torrent Pharma (BSE) 3504.35 (1.22%)	M.Cap ( in Cr)118603.13

Shareholding Pattern

	PROMOTERS	44.08%
	NON-INSTITUTION	37.43%
	MUTUAL FUNDS/UTI	5.16%
	FI/BANKS/INSURANCE	3.35%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	2.95
LIC MF Healthcare F...	2.59
SBI Healthcare Opp ...	2.39
Baroda BNP Paribas ...	2.13
Baroda BNP Paribas ...	2.01
Baroda BNP Paribas ...	1.71
Invesco India Manuf...	1.58

Risk Disclosures on Derivatives

Smart Quotes

CONCORD BIOTECH LTD.